The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Intraperitoneal Therapy for Peritoneal Cancer
Open accessAbstract
Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA. Peritoneal metastases are common owing to locoregional spread and distant metastases of extraperitoneal cancers. A logical treatment is intraperitoneal therapy, as multiple studies have shown significant targeting advantage for this treatment, including significant survival benefits in stage III, surgically debulked ovarian cancer patients. However, the clinical use of intraperitoneal therapy has been limited, in part, by toxicity, owing to the use of indwelling catheters or high drug exposure, by inadequate drug penetration into bulky tumors (>1 cm) and by the lack of products specifically designed and approved for intraperitoneal treatments. This article provides an overview on the background of peritoneal metastasis, clinical research on intraperitoneal therapy, the pharmacokinetic basis of drug delivery in intraperitoneal therapy and our development of drug-loaded tumor-penetrating microparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Biodegradable polymers for use in surgery—polyglycolic/poly(actic acid) homo- and copolymers: 1
Gilding, D. K., & Reed, A. M. (1979) · Polymer · doi:10.1016/0032-3861(79)90009-0 · Cited by 1,345
Cited by
Yin, M., Li, X., Tan, S., Zhou, H. J., Ji, W., Bellone, S., Xu, X., Zhang, H., Santin, A. D., Lou, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87252 · Cited by 417
Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies
Liston, D. R., & Davis, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3083 · Cited by 395
Research progress in membrane fusion-based hybrid exosomes for drug delivery systems
Liu, A., Yang, G., Liu, Y., & Liu, T. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.939441 · Cited by 88
EO9 (Apaziquone): from the clinic to the laboratory and back again
Phillips, R. M., Hendriks, H. R., Peters, G. J., & on behalf of the EORTC‐Pharmacology and Molecular Mechanism Group (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01996.x · Cited by 79
Metadata
- Authors
- Lu, Z., Wang, J., Wientjes, M. G., & Au, J. L.-S.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2010-11-09
- Volume
- 6
- Issue
- 10
- Pages
- 1625-1641
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2068823574
- Cited by
- 160
- References
- 3
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intraperitoneal Therapy for Peritoneal Cancer. https://app.cochat.ai/papers/10.2217/fon.10.100
- The paper
- Lu, Z., Wang, J., Wientjes, M. G., & Au, J. L.-S. (2010). Intraperitoneal Therapy for Peritoneal Cancer. Future Oncology. https://doi.org/10.2217/fon.10.100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.